PSI CRO will meet with sponsors at ESMO 2026 to discuss oncology enrollment strategy, data quality, and execution across pivotal programs.
Published
Signal category
Presence & Recognition
Quote
“At ESMO - European Society for Medical Oncology 2026, PSI will meet with sponsors to discuss how to maintain enrollment momentum, data quality, and predictable execution across pivotal oncology programs.”
— PSI CRO team
Company
- Industry
- Pharmaceutical Manufacturing
- Location
- Zug, CH
- Company size
- 2,969 employees
PSI is a leading full-service global Contract Research Organization whose key strength is predictable patient enrollment across multiple therapeutic areas. PSI is known in the industry as a CRO focused on ‘on-time project delivery’. This is achieved through investing substantial effort and MD resources into performing quality feasibility assessments that provide an accurate predictor of study timelines. PSI’s global reach allows us to run clinical trials across multiple continents, in 50+ countries around the world. PSI’s reputation is that of a 'no-nonsense' CRO focused on timely patient enrollment and project delivery. An exceptionally high repeat and referral business rates alongside low staff turnover are indicative of our commitment to be the best CRO in the world as measured by our clients and our employees. http://www.psi-cro.com